Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.66 +0.11 (+0.81%)

Streaming Delayed Price Updated: 2:36 PM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis ↗

August 09, 2021

Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap.

Via Talk Markets

Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

NTLA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Where Intellia Therapeutics Stands With Analysts ↗

August 06, 2021

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst rati...

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

August 06, 2021

Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price...

Via Benzinga

Why Shares of Intellia Therapeutics Are Jumping Today ↗

August 05, 2021

More progress in the pipeline has investors bullish on the company's shares.

Via The Motley Fool

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗

August 05, 2021

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.

Via InvestorPlace

Why Intellia Therapeutics' Stock Is Trading Higher Today ↗

August 05, 2021

Intellia Therapeutics Inc (NASDAQ:NTLA) is trading si...

Via Benzinga

Why Intellia Therapeutics Shares Are Trading Higher Today ↗

August 05, 2021

...

Via Benzinga

Unusual Options Activity Insight: Intellia Therapeutics ↗

July 30, 2021

On Friday, shares of Intellia Therapeutics (NASDAQ:NTLA) ...

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio ↗

July 27, 2021

The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.

Via The Motley Fool

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding ↗

July 15, 2021

It's a good time to be a gene-editing company.

Via The Motley Fool

Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗

July 13, 2021

The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM...

Via Benzinga

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results ↗

July 11, 2021

There are still some key unanswered questions for the biotech's promising gene-editing therapy.

Via The Motley Fool

US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA ↗

July 10, 2021

Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia.

Via Talk Markets

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

Here's Why Regeneron Gained 11% Last Month ↗

July 07, 2021

The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.

Via The Motley Fool

2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't ↗

July 04, 2021

After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.

Via The Motley Fool

Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus ↗

July 02, 2021

The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.

Via Investor's Business Daily

Topics Initial Public Offering Stocks

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now ↗

July 01, 2021

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

Via The Motley Fool

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond ↗

June 30, 2021

Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today